Genome-environment interactions that modulate aging: powerful targets for drug discovery
Open accessAbstract
Aging is the major biomedical challenge of this century. The percentage of elderly people, and consequently the incidence of age-related diseases such as heart disease, cancer, and neurodegenerative diseases, is projected to increase considerably in the coming decades. Findings from model organisms have revealed that aging is a surprisingly plastic process that can be manipulated by both genetic and environmental factors. Here we review a broad range of findings in model organisms, from environmental to genetic manipulations of aging, with a focus on those with underlying gene-environment interactions with potential for drug discovery and development. One well-studied dietary manipulation of aging is caloric restriction, which consists of restricting the food intake of organisms without triggering malnutrition and has been shown to retard aging in model organisms. Caloric restriction is already being used as a paradigm for developing compounds that mimic its life-extension effects and might therefore have therapeutic value. The potential for further advances in this field is immense; hundreds of genes in several pathways have recently emerged as regulators of aging and caloric restriction in model organisms. Some of these genes, such as IGF1R and FOXO3, have also been associated with human longevity in genetic association studies. The parallel emergence of network approaches offers prospects to develop multitarget drugs and combinatorial therapies. Understanding how the environment modulates aging-related genes may lead to human applications and disease therapies through diet, lifestyle, or pharmacological interventions. Unlocking the capacity to manipulate human aging would result in unprecedented health benefits.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inhibition of the mTOR pathway (using rapamycin), which extends lifespan in a variety of model organisms, is an effective SASP suppressor.
“For instance, inhibition of the mTOR pathway (using the drug rapamycin), which has been shown to extend lifespan in a variety of model organisms (de Magalhaes et al., 2012;Harrison et al., 2009), is an effective SASP suppressor (Correia-Melo et al., 2016;Herranz et al., 2015;Laberge et al., 2015).”
From Stress, cell senescence and organismal ageing (2018) · cites this paper as de Magalhaes et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 134 · Cited by 136
Research works printed but not linked: 1
- Stipp D (2010) The Youth Pill: Scientists at the Brink of an Anti-Aging Revolution, Penguin Books, London.
- Authors
- de Magalhães, J. P., Wuttke, D., Wood, S. H., Plank, M., & Vora, C.
- Affiliations
- University of Liverpool (GB)
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 64
- Issue
- 1
- Pages
- 88-101
- ISSN
- 0031-6997 (ISSN-L)
- PMC
- PMC3250080
- OpenAlex
- W2098016440
- Cited by
- 136
- References
- 134
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 10 · 2023: 8 · 2022: 11 · 2021: 15 · 2020: 4 · 2019: 1 · 2018: 6 · 2017: 11 · 2016: 10 · 2015: 13 · 2014: 12 · 2013: 12 · 2012: 12
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Pharmacological Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Funders
- Ellison Medical Foundation
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/H008497/1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- aging, gene-environment interaction, caloric restriction, longevity, model organisms, drug discovery, IGF-1 receptor, FOXO3, age-related diseases, multi-target drugs, combination therapy
- MeSH terms
- Aging, Animals, Health, Humans, Caloric Restriction, Drug Discovery, Gene-Environment Interaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review